OCRELIZUMAB (Ocrevus) prior authorization at Blue Cross NC
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross NC requires CD20-directed Cytolytic Antibody prior-authorization documentation for OCRELIZUMAB (Ocrevus): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Blue Cross NC reviews OCRELIZUMAB (Ocrevus) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody. Blue Cross NC-specific context: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross NC's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Step therapy via Prime Therapeutics
- Blue Premier value-based arrangement disputes
- Out-of-network reductions
- Specialty drug PA
OCRELIZUMAB (Ocrevus)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Site-of-care reduction (home infusion vs hospital)
- Step therapy
Brand: Ocrevus. First FDA-approved DMT for primary progressive MS.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Blue Cross NC denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.bluecrossnc.com/providers) with the same packet plus an applicable, current clinical source supporting OCRELIZUMAB (Ocrevus)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Blue Cross NC denial on DenialHelp.
Contact Blue Cross NC
- Provider portal: https://www.bluecrossnc.com/providers
Frequently asked questions
What documentation does Blue Cross NC need for OCRELIZUMAB (Ocrevus) prior auth?
Blue Cross NC's typical PA packet for OCRELIZUMAB (Ocrevus): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Blue Cross NC?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for OCRELIZUMAB (Ocrevus) at Blue Cross NC?
Preparation scenarios to check against the current notice and policy include: Step therapy via Prime Therapeutics; Blue Premier value-based arrangement disputes; Out-of-network reductions. These are not measured frequency claims. For OCRELIZUMAB (Ocrevus), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with Blue Cross NC on OCRELIZUMAB (Ocrevus)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the OCRELIZUMAB (Ocrevus) PA packet
Open ApprovalHelp — generate a OCRELIZUMAB (Ocrevus) prior-auth packet tailored to Blue Cross NC's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com